A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of bevacizumab and sunitinib given in
combination for kidney cancer. The drugs act to stop blood vessel growth but in different
ways. They have not been studied together in a previous study. We also want to find out what
effects (good and bad) the combination of bevacizumab and sunitinib have on you and your
tumor.